Key Takeaways
- Evom AI raised a new round (Seed) from Klim Ventures.
- Sector: Artificial Intelligence (AI), Healthcare, Healthtech & Medtech.
- Geography: South Korea.
Analysis
South Korean medical AI innovator, Evom AI, has successfully closed a seed bridge funding round, bolstering its commercialization efforts following significant regulatory achievements. The investment, led by Klim Ventures, follows an initial seed investment from the same firm in September 2025. While the specific financial terms of this latest injection remain undisclosed, the funding signifies a crucial step for the company as it transitions from its development phase to becoming a recognized supplier in the cardiac diagnostics market.
This financial milestone is closely aligned with Evom AI's recent success in navigating stringent regulatory pathways. The company secured digital medical device registration from South Korea's Ministry of Food and Drug Safety (MFDS) in March for its flagship product, Evom FastEcho. This advanced echocardiography solution automates the classification of 42 cardiac views and calculates 56 critical structural measurements, significantly enhancing the efficiency of scan interpretation for clinicians. Further solidifying its operational readiness, Evom AI also passed its initial Korea Good Manufacturing Practice (KGMP) audit for digital medical devices in May, demonstrating a robust quality management system.
These regulatory clearances are pivotal, paving the way for Evom AI to expand its portfolio of artificial intelligence solutions targeting cardiac conditions. The company is now positioned to broaden its offerings beyond echocardiography, with plans to integrate its AI capabilities into electrocardiography (ECG) applications. This strategic expansion aims to create a comprehensive suite of trusted cardiac AI tools for real-world clinical use.
Founded by seasoned professionals with prior experience at leading AI and healthcare technology firms like Lunit, Evom AI's team brings deep expertise in AI development, clinical research, global regulatory affairs, and commercialization. Their collective focus is on developing predictive AI and early diagnostic tools for cardiovascular diseases, a sector experiencing substantial growth driven by an aging global population and increasing prevalence of heart conditions. The global AI in healthcare market is projected to reach hundreds of billions of dollars in the coming years, with diagnostic imaging and AI-powered analytics being key growth drivers.
Hyunsub Nam, CEO of Evom AI, emphasized that these recent funding and regulatory successes mark a definitive shift for the company. He stated that the immediate priority is the rapid productization of their ECG solution, aiming to establish a trusted cardiac AI portfolio. This focus on market readiness and clinical validation is essential for gaining traction in the competitive MedTech space.
Hongkyu Nam, CEO of Klim Ventures, lauded Evom AI's exceptional execution speed. He highlighted the impressive feat of obtaining both MFDS registration and KGMP certification within a year of the initial investment. This rapid progress, he noted, is a testament to the founding team's unwavering commitment to embedding regulatory compliance and quality assurance from the project's inception, a critical factor for success in the highly regulated medical device industry.